SCHEDULE: Citadel Discloses Minimal Stake in VYNE Therapeutics
Beneficial Ownership Report (Amendment)
Citadel and its affiliates, including Kenneth Griffin, reported a 0.0% beneficial ownership in VYNE Therapeutics Inc. common stock in a recent Schedule 13G amendment.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 3,669 shares of VYNE Therapeutics Inc. common stock.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively beneficially own 63 shares of VYNE Therapeutics Inc. common stock.
- Kenneth Griffin beneficially owns an aggregate of 3,732 shares of VYNE Therapeutics Inc. common stock, encompassing the holdings of the affiliated entities.
- The aggregate beneficial ownership by all reporting persons represents 0.0% of VYNE Therapeutics Inc.'s total outstanding shares.
- The total outstanding shares of VYNE Therapeutics Inc. were 25,472,165 as of August 7, 2025, based on the issuer's Form 10-Q filed on August 14, 2025.
- The filing indicates a passive investment purpose, stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of a very small, passive ownership stake (0.0%) by institutional investors. It provides no new information regarding the issuer's performance or strategic direction, thus having a neutral sentiment.
Future Outlook
NA
Industry Context
Schedule 13G filings are routine disclosures by passive institutional investors who hold a significant, but non-controlling, stake in a public company. This amendment indicates a continued, albeit minimal (0.0%), passive investment by Citadel entities in VYNE Therapeutics, reflecting standard portfolio management activities rather than a strategic or activist stake. Such filings are common and typically do not signal a change in the issuer's operational or strategic direction.
Stakeholder Impact
- Minimal impact on shareholders due to the extremely low percentage of beneficial ownership (0.0%) reported by the institutional investors, indicating a passive, non-influential stake.
Key Dates
| Date | Description |
|---|---|
| 2025-08-07 | Date as of which 25,472,165 shares of VYNE Therapeutics Inc. were outstanding, according to the issuer's Form 10-Q. |
| 2025-08-14 | Date the issuer's Form 10-Q was filed with the Securities and Exchange Commission, reporting shares outstanding. |
| 2025-09-30 | Date of event which required the filing of this Schedule 13G Amendment No. 3. |
| 2025-11-14 | Date of signing and filing of this Schedule 13G Amendment No. 3 by the Reporting Persons. |
Keywords
VYNE Therapeutics, Citadel, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.